transcutan
immun
tci
system
use
skin
immun
function
promis
needlefre
easytous
lowinvas
vaccin
altern
convent
inject
vaccin
method
develop
effect
tci
system
essenti
establish
fundament
techniqu
technolog
deliv
antigen
protein
antigenpres
cell
epidermi
dermi
overcom
barrier
function
stratum
corneum
review
provid
outlin
recent
trend
develop
techniqu
deliveri
antigen
protein
technolog
use
enhanc
tci
system
also
introduc
basic
clinic
research
involv
tci
system
incorpor
sever
origin
devic
infecti
diseas
common
caus
death
account
approxim
onethird
fatal
worldwid
recent
wave
transnat
migrat
peopl
materi
enhanc
develop
transport
facil
chang
social
structur
war
increas
global
spread
emerg
infect
sever
acut
respiratori
syndrom
avian
influenza
viru
addit
declin
sanit
onset
drugresist
pathogen
organ
increas
spread
reemerg
infecti
diseas
tuberculosi
malaria
although
major
treatment
infecti
diseas
antibiot
administr
fundament
prophylaxi
vaccin
biolog
prepar
improv
immun
particular
diseas
vaccin
develop
long
histori
progress
recent
develop
new
approach
technolog
base
advanc
made
field
bacteriolog
virolog
molecular
biolog
convent
vaccin
howev
perform
mainli
inject
sever
inher
problem
pain
need
train
personnel
associ
needlerel
diseas
injuri
storag
transport
issu
area
vaccin
coverag
infect
low
due
failur
followup
well
lack
train
medic
personnel
facil
reus
needl
caus
death
least
million
peopl
per
year
hepat
b
aid
thu
develop
needlefre
easytous
lowinvas
vaccin
method
urgent
task
advantag
overcom
inher
problem
vaccin
inject
transcutan
immun
tci
intranas
immun
ini
attract
attent
altern
vaccin
rout
ini
needlefre
vaccin
method
highli
expect
hope
vaccin
procedur
stimul
mucos
system
immun
respons
mucos
antigen
ag
specif
immun
respons
howev
weak
thu
necessari
develop
mucos
vaccin
adjuv
develop
mucos
vaccin
cholera
toxin
ct
heatlabil
enterotoxin
lt
potent
mucos
adjuv
recent
report
show
human
vaccin
contain
inactiv
influenza
viru
lt
adjuv
result
high
incid
bell
palsi
therefor
mucos
vaccin
adjuv
high
efficaci
safeti
purpos
clinic
applic
necessari
skin
import
immun
function
proinflammatori
organ
epidermi
dermi
highli
popul
dendrit
cell
dc
potent
agpres
cell
apc
import
immunostimulatori
migratori
activ
fig
langerhan
cell
lc
epidermi
dermal
dc
ddc
dermi
import
induct
agspecif
immun
respons
tci
system
thu
ag
effici
deliv
lc
ddc
resid
epiderm
layer
dermi
tci
might
elicit
effect
immun
respons
howev
difficulti
overcom
develop
tci
system
uppermost
layer
epidermi
stratum
corneum
sc
consist
layer
latten
enucl
keratinfil
corneocyt
surround
lamella
around
eight
lipid
bilay
lipid
bilay
consist
fig
skin
immun
system
skin
enrich
variou
immunocompet
cell
lc
keratinocyt
sever
ddc
keratinocyt
mainli
involv
induct
innat
immun
lc
ddc
captur
extern
ag
migrat
region
lymph
node
present
ag
cell
activ
agspecif
cell
b
cell
activ
cell
b
cell
migrat
tissu
induc
agspecif
immun
respons
primarili
cholesterol
free
fatti
acid
ceramid
sc
princip
barrier
penetr
substanc
difficult
effici
deliv
adequ
ag
cutan
apc
sc
appli
ag
onto
bare
skin
therefor
order
develop
effect
tci
system
technolog
must
establish
promot
ag
penetr
sc
review
outlin
mechan
skin
immun
system
recent
transcutan
antigen
protein
deliveri
techniqu
technolog
devic
furthermor
introduc
progress
made
research
practic
applic
tci
basic
preclin
clinic
investig
skin
access
site
tci
act
physic
barrier
also
immunolog
barrier
enrich
variou
immunocompet
cell
lc
keratinocyt
ddc
fig
special
lc
ddc
take
import
role
induct
agspecif
immun
respons
noninflammatori
condit
lc
ddc
part
immatur
mean
strong
endocyt
capac
extern
ag
enter
skin
lc
ddc
captur
increas
express
costimulatori
factor
play
role
present
ag
cell
permit
movement
apc
away
skin
subsequ
entri
local
within
drain
lymph
node
lc
ddc
present
ag
tcell
activ
agspecif
cell
b
cell
keratinocyt
also
involv
induct
agspecif
immun
respons
activ
innat
immun
system
keratinocyt
could
effect
convert
exogen
stimuli
host
homeostat
respons
particular
express
numer
tolllik
receptor
surfac
endosom
also
anoth
type
receptor
discov
keratinocyt
nucleotid
bindingdomain
oligomer
domainlik
receptor
receptor
allow
keratinocyt
recogn
bacteri
compon
name
patternassoci
molecular
pattern
pamp
case
extern
ag
enter
keratinocyt
produc
cytokin
chemokin
constitut
signal
necessari
lc
ddc
migrat
region
lymph
node
like
keratinocyt
lc
ddc
express
receptor
contribut
mainten
inflammatori
environ
inflammatori
microenviron
innat
immun
aris
first
contact
vaccin
compon
contribut
differ
extent
product
proinflammatori
molecul
strongli
contribut
primari
event
adapt
immun
respons
activ
skinresid
apc
vaccin
ag
administr
skin
agspecif
immun
respons
induc
mechan
thu
skin
clearli
attract
organ
ag
deliveri
elicit
immun
respons
sever
type
profession
apc
inhabit
healthi
skin
studi
function
skinresid
apc
involv
induct
skin
immun
investig
fig
mice
skinresid
apc
classifi
two
categori
lc
epidermi
ddc
dermi
lc
ddc
seem
induc
immun
respons
respect
howev
studi
suggest
lc
involv
induct
immun
respons
year
also
report
suggest
exist
sever
ddc
subset
publish
mice
gener
assum
express
langerin
skin
strictli
confin
lc
epidermi
view
alter
current
data
indic
larg
popul
langerinposit
cell
correspond
ddc
classic
langerinneg
ddc
express
macrophag
lipidbas
vesicl
nanobio
interact
flexibl
bilay
mix
sc
disrupt
ag
protect
extern
environ
disadvantag
low
effici
marker
wherea
langerinposit
ddc
express
without
also
report
ddc
exist
dermi
especi
ddc
neither
dermal
ddc
lc
shown
crucial
role
induct
agspecif
cell
immun
respons
recent
progress
made
identifi
potenti
homolog
mous
ddc
subset
examin
human
ddc
human
skin
apc
also
divid
two
group
basi
local
lc
epidermi
ddc
dermi
epiderm
lc
preferenti
induc
differenti
cell
secret
cell
cytokin
effici
crossprim
naiv
cell
human
ddc
distinguish
sever
subset
ddc
ddc
ddc
phenotyp
function
homeostat
inflam
skin
human
ddc
ddc
express
langerin
classifi
base
reciproc
express
thought
equival
mous
ddc
howev
rel
contribut
subset
gener
immun
toler
still
unclear
yet
special
differ
popul
becom
appar
human
ddc
promot
antibodi
product
b
cell
addit
dc
exhibit
special
crosspres
function
express
number
marker
associ
mous
dc
although
immun
mechan
skin
remain
complet
elucid
analys
investig
improv
knowledg
skin
immun
system
could
lead
induct
optim
immun
respons
humor
immun
cellular
immun
infecti
diseas
previous
note
sc
act
physic
barrier
penetr
substanc
skin
variou
pharmaceut
approach
devic
develop
enabl
tci
system
overcom
penetr
barrier
sc
section
techniqu
technolog
devic
use
enhanc
tci
review
tabl
electropor
method
increas
permeabl
skin
appli
singl
multipl
shortdur
puls
wide
use
loosen
cell
surfac
allow
deliveri
molecul
live
cell
highvoltag
puls
v
deliv
skin
surfac
microchannel
local
transport
region
creat
lipid
bilay
membran
includ
sc
zhao
et
al
report
tci
peptid
deriv
ovalbumin
ova
cpg
oligodeoxi
nucleotid
adjuv
use
electropor
could
induc
ovaspecif
cell
respons
equival
induc
intraderm
inject
indic
tci
use
electropor
induc
agspecif
immun
respons
howev
method
requir
powersuppli
equip
thu
may
use
procedur
medic
institut
achiev
optim
eas
selfadministr
addit
disrupt
sc
skin
barrier
may
lead
secondari
infect
iontophoresi
method
enhanc
transport
ionic
charg
molecul
biolog
membran
pass
direct
period
electr
current
electrolyt
solut
appropri
electrod
polar
techniqu
appli
field
transderm
drug
deliveri
shown
sever
group
promot
penetr
peptid
protein
insulin
calcitonin
botulinum
toxin
sc
combin
electropor
iontophoresi
make
substanc
penetr
even
effect
report
iontophoresi
enhanc
penetr
macro
molecul
sc
skin
thu
applic
method
tci
system
expect
howev
sever
problem
lack
conveni
risk
secondari
infect
remain
requir
powersuppli
equip
may
break
cutan
barrier
sonophoresi
method
enhanc
substanc
penetr
disrupt
structur
sc
lowfrequ
ultrasound
cavit
format
gaseou
caviti
ultrasoundcoupl
medium
upon
exposur
ultrasound
involv
rapid
growth
collaps
bubbl
transient
cavit
slow
oscillatori
motion
bubbl
stabl
cavit
ultrasound
field
oscil
collaps
cavit
bubbl
disord
lipid
bilay
sc
therebi
enhanc
transport
dahlan
et
al
shown
tci
use
lowfrequ
ultrasound
tetanu
toxoid
tt
induc
antitt
igg
neutral
antibodi
interestingli
tezel
et
al
report
ultrasound
treatment
induc
lc
activ
enhanc
agspecif
immun
respons
suggest
act
physic
adjuv
although
tci
use
sonophoresi
induc
agspecif
igg
antibodi
advantag
activ
immunocompet
cell
method
requir
powersuppli
equip
disrupt
cutan
barrier
thu
sever
issu
term
use
safeti
jet
injector
devic
use
pressur
deliv
substanc
skin
first
devic
multipleus
nozzl
jet
injector
larg
number
patient
vaccin
fluid
stream
nozzl
howev
devic
longer
use
crosscontamin
recent
develop
effort
result
dispos
syring
jet
injector
simon
et
al
report
clinic
studi
immunogen
trival
inactiv
influenza
vaccin
administr
lectrajet
ra
dispos
syring
jet
injector
clear
sale
use
us
food
drug
administr
jet
injector
system
agspecif
immun
respons
induc
administr
method
simpl
ampoul
need
way
convent
inject
system
indic
need
coldchain
transport
storag
patch
formul
one
commonli
use
system
tci
sever
group
report
tci
use
gauz
patch
adher
patch
induc
agspecif
immun
respons
applic
ltcontain
singlepli
polyesterrayon
gauz
patch
onto
human
skin
increas
antilt
igg
titer
serum
although
group
also
report
develop
tci
system
practic
use
show
safeti
efficaci
system
compris
gauz
patch
tci
devic
requir
gauz
patch
satur
ag
solut
applic
skin
tci
system
inconveni
requir
cold
storag
transport
ag
solut
convent
inject
vaccin
system
addit
disadvantag
patchbas
tci
system
requir
skin
prepar
system
sp
cyanoacryl
skin
surfac
strip
csss
procedur
remov
sc
patch
applic
improv
ag
penetr
skin
method
may
carri
risk
increas
sensit
secondari
infect
disrupt
sc
cutan
barrier
safeti
issu
thu
develop
easytous
safer
patchbas
tci
system
desir
research
group
develop
hydrogel
patch
tci
devis
made
safe
materi
alreadi
appli
human
tci
formul
use
hydrogel
patch
shown
induc
effect
immun
respons
tetanu
diphtheria
applic
absent
treatment
anim
model
also
demonstr
safeti
efficaci
perform
clinic
studi
tci
formul
vaccin
tetanu
diphtheria
human
without
disrupt
sc
patchbas
tci
system
prepar
tci
formul
drop
ag
solut
hydrogel
patch
leav
room
temperatur
hydrogel
patch
formul
immers
texasr
tr
label
ova
solut
form
concentr
ag
layer
surfac
fig
water
ag
solut
absorb
hydrogel
polym
import
deliv
antigen
protein
skinresid
apc
induct
agspecif
immun
respons
therefor
analyz
biodistribut
ag
transcutan
administr
hydrogel
patch
mark
penetr
ag
epiderm
layer
intact
skin
applic
hydrogel
patch
contain
trova
auricl
skin
mice
fig
human
tissueengin
skin
model
hydrogel
patch
also
promot
penetr
antigen
protein
sc
although
theori
convent
transderm
drug
deliveri
suggest
skin
structur
composit
allow
penetr
materi
larger
da
transcutan
vaccin
system
deliv
antigen
protein
kda
epiderm
layer
propos
follow
mechan
penetr
ag
skin
first
concentr
antigen
protein
surfac
patch
might
gener
high
concentr
gradient
antigen
protein
skin
critic
produc
drive
forc
need
acceler
passiv
diffus
distribut
theori
support
observ
distribut
trova
epiderm
layer
simpli
result
spread
trova
solut
intact
skin
surfac
applic
filter
paper
immers
ag
solut
enhanc
either
ag
penetr
antibodi
titer
second
humect
hydrat
skin
hydrogel
patch
appli
might
loosen
intercellular
gap
sc
contribut
improv
penetr
watersolubl
substanc
accord
observ
ag
penetr
via
patch
system
occur
mainli
intercellular
gap
sc
fact
sever
report
increas
water
content
sc
lead
increas
membran
fluiditi
decreas
electr
resist
although
possibl
antigen
protein
penetr
epiderm
layer
hair
follicl
report
hair
follicl
allow
even
nanoparticl
reach
epiderm
layer
skin
hydrogel
patch
enhanc
ag
penetr
tissueengin
skin
without
pore
suggest
pathway
contribut
littl
penetr
ag
skin
promot
hydrogel
patch
combin
mechan
patch
vaccin
system
promot
penetr
watersolubl
macromolecular
protein
sc
shown
fig
yellow
fluoresc
spot
indic
trova
local
accord
lc
local
observ
merg
imag
epiderm
sheet
lymph
node
section
prepar
mice
intact
skin
suggest
lc
cell
critic
induct
potent
immun
respons
captur
antigen
protein
penetr
skin
migrat
region
lymph
node
thu
agcaptur
lc
migrat
epiderm
layer
region
lymph
node
would
greatli
contribut
trigger
amplifi
agspecif
immun
respons
induc
transcutan
vaccin
use
hydrogel
patch
formul
anim
model
tetanu
diphtheria
infect
vaccin
efficaci
tci
use
hydrogel
patch
evalu
tci
use
hydrogel
patch
elicit
toxoidspecif
immun
respons
serum
titer
antibodi
tci
group
equival
greater
subcutan
immun
sci
group
fig
f
rat
vaccin
combin
tt
dt
tt
dtspecif
igg
antibodi
detect
serum
effici
rat
vaccin
toxoid
alon
suggest
tci
use
hydrogel
patch
applic
combin
vaccin
mix
inoculationi
recommend
vaccin
tci
formul
suitabl
practic
use
also
demonstr
tci
use
hydrogel
patch
contain
tt
dt
induc
littl
advers
reaction
local
system
toxic
assess
indic
hydrogel
patchbas
tci
formul
noninvas
vaccin
method
addit
basi
igg
subclass
analysi
suggest
tci
use
hydrogel
patch
formul
predominantli
elicit
immun
respons
rather
immun
respons
analys
necessari
elucid
mechan
patch
vaccin
hydrogel
patchbas
tci
system
simpli
prepar
manag
tci
formul
like
gener
foment
concentr
ag
layer
surfac
hydrogel
patch
tci
system
use
hydrogel
patch
enhanc
ag
penetr
skin
induc
agspecif
immun
respons
singl
applic
onto
skin
surfac
without
disrupt
sc
superior
patchbas
tci
formul
term
avoid
secondari
infect
break
skin
barrier
patch
formul
hydrogel
patch
less
effect
promot
penetr
particul
insolubl
ag
sc
practic
vaccin
ag
particul
state
exampl
less
virul
strain
bacteria
develop
differ
tci
system
effect
use
ag
form
need
microneedl
array
contain
mani
micrometers
needl
creat
transport
pathway
larg
enough
protein
nanoparticl
small
enough
avoid
pain
microneedl
array
penetr
sc
barrier
deliv
ag
immunocompet
cell
skin
effici
tci
system
addit
use
dispos
array
suitabl
selfadministr
thu
microneedl
attract
devic
develop
effect
tci
system
microneedl
first
conceptu
drug
deliveri
patent
sinc
sever
type
microneedl
develop
classifi
four
type
respect
mechan
action
solid
microneedl
pretreat
skin
increas
permeabl
microneedl
coat
drug
dissolv
skin
polym
microneedl
encapsul
drug
fulli
dissolv
skin
hollow
microneedl
infus
drug
skin
tradit
microneedl
array
made
silicon
metal
stainless
steel
titanium
report
earli
stage
develop
clinic
use
microneedl
array
face
seriou
obstacl
needl
microneedl
array
fractur
remain
skin
creat
safeti
issu
convent
microneedl
array
suffer
risk
fractur
microneedl
fragment
skin
therefor
microneedl
system
made
biocompat
biodegrad
polym
began
develop
superior
safeti
led
earli
clinic
use
system
howev
remain
risk
break
cutan
barrier
insert
microneedl
skin
manufactur
dissolv
microneedl
technic
innov
requir
allow
ag
incorpor
matrix
microneedl
materi
use
mild
procedur
caus
decreas
antigen
compromis
materi
strength
research
group
develop
dissolv
microneedl
array
microhyala
mh
tci
devic
fabric
use
micromold
technolog
biocompat
sodium
hyaluron
base
materi
approach
demonstr
effect
vaccin
effect
compar
convent
inject
system
develop
dissolv
microneedl
array
mh
mention
made
sodium
hyaluron
base
materi
fig
success
fabric
sever
type
mh
variou
form
length
konideshap
mh
needl
length
coneshap
mh
needl
length
g
intranas
applic
ha
g
combin
ct
g
adjuv
twice
interv
two
week
last
vaccin
mice
infect
intranas
pfu
viru
indic
point
sera
collect
mice
assay
titer
haspecif
igg
elisa
b
bodi
weight
measur
day
infect
present
percentag
origin
weight
infect
day
c
six
day
infect
lung
collect
mice
number
virus
lung
homogen
determin
plaqu
assay
system
data
express
mean
se
result
b
c
mice
arrowhead
indic
vaccin
point
fig
microneedl
mh
dissolv
water
skin
thu
danger
remain
skin
make
mh
safer
tradit
microneedl
array
made
metal
stainless
steel
fact
microneedl
tip
fulli
dissolv
h
fig
applic
mh
caus
temporari
skin
irrit
skin
barrier
function
insert
recov
immedi
suggest
hole
caus
insert
mh
close
quickli
result
suggest
low
probabl
caus
secondari
infect
applic
mh
observ
skin
section
applic
mh
contain
fluorescein
isothiocyan
fitc
silica
particl
clearli
detect
fig
suggest
mh
deliv
particul
ag
epidermi
dermi
without
regard
ag
form
addit
mh
size
use
control
depth
ag
deliveri
mean
mh
might
deliv
ag
specif
skinresid
apc
lc
epidermi
sever
ddc
dermi
examin
efficaci
vaccin
influenza
hemagglutinin
ha
ag
particul
ag
influenza
viru
challeng
tci
ha
alon
elicit
product
haspecif
function
igg
antibodi
equival
intramuscular
immun
imi
ha
alon
ini
combin
ha
ct
adjuv
fig
hand
littl
antiha
iga
antibodi
detect
tci
imi
group
challeng
influenza
viru
mice
tci
group
show
remark
weight
loss
similar
imi
group
ini
ct
group
fig
addit
viru
titer
lung
tci
group
detect
limit
fig
demonstr
tci
system
provid
protect
equal
imi
ini
adjuv
ini
system
mucos
vaccin
adjuv
high
efficaci
safeti
purpos
clinic
applic
necessari
compar
ini
system
tci
could
effici
elicit
agspecif
vaccin
effect
without
adjuv
advantag
tci
system
addit
vaccin
efficaci
tci
use
mh
also
demonstr
tetanu
diphtheria
malaria
infect
model
basi
result
tci
system
use
mh
suggest
induc
agspecif
immun
respons
vaccin
ag
solubl
ag
insolubleag
particul
ag
convent
tci
system
fail
thu
conclud
tci
system
use
mh
dissolv
skin
effect
confer
protect
immun
without
caus
seriou
advers
reaction
anim
model
convent
microneedl
array
made
metal
stainless
steel
difficulti
clinic
applic
needl
microneedl
array
fractur
remain
skin
seriou
problem
howev
microneedl
mh
dissolv
water
skin
thu
danger
remain
skin
indic
tci
use
mh
would
attract
vaccin
method
term
safeti
efficaci
recent
studi
suggest
nanoparticl
attract
mean
transcutan
ag
deliveri
disrupt
sc
result
nanobio
interact
skin
lipid
antigen
protein
encapsul
nanoparticl
deliv
sc
skin
research
report
nanoparticl
vaccin
compound
penetr
via
hair
follicl
high
densiti
apc
enhanc
immun
respons
numer
nanoparticl
system
avail
includ
polymer
poli
dllacticcoglycol
acid
poli
lactic
acid
nanoparticl
biodegrad
chitosan
nanoparticl
metal
nanoparticl
addit
lipidbas
vesicl
liposom
transfersom
niosom
structur
similar
biolog
membran
facilit
skin
penetr
mix
sc
lipid
flexibl
liposom
fl
carri
remark
amount
lipid
mass
skin
therefor
advantag
promot
cutan
drug
disposit
disrupt
skin
barrier
flexibl
bilay
also
report
fl
stimul
transcutan
immun
respons
act
adjuv
design
novel
formul
especi
nanoscal
system
nanoparticl
lipidbas
vesicl
help
protect
ag
extern
environ
keep
long
term
activ
properti
conduct
applic
transcutan
vaccin
howev
develop
novel
nanoscal
system
tci
limit
low
effici
elicit
robust
immun
respons
diffus
vaccin
worldwid
includ
develop
countri
patch
formul
microneedl
suitabl
eas
use
efficaci
sever
research
group
conduct
clinic
studi
tci
use
patch
formul
microneedl
system
recent
year
tabl
glenn
et
al
first
report
result
tci
use
patch
human
applic
patch
contain
lt
ag
result
robust
ltspecif
antibodi
respons
addit
group
use
lt
investig
patch
vaccin
travel
diarrhea
phase
ii
clinic
trial
found
ltpatch
recipi
protect
moderatetosever
diarrhea
protect
efficaci
pe
sever
diarrhea
pe
ltpatch
recipi
becam
ill
shorter
episod
diarrhea
vs
day
fewer
loos
stool
vs
recipi
placebo
sinc
numer
studi
devic
serv
simpl
easytous
lowinvas
tci
system
undertaken
etchart
et
al
show
tci
human
adult
volunt
liveattenu
measl
induc
agspecif
immun
respons
phase
iii
clinic
studi
combadier
et
al
demonstr
tci
inactiv
influenza
vaccin
induc
signific
increas
influenza
vaccinespecif
respons
compar
obtain
intramuscular
rout
howev
tci
system
requir
cyanoacryl
skin
surfac
strip
ag
deliveri
skin
might
caus
skin
irrit
one
side
effect
microneedlebas
tci
system
also
appli
clinic
trial
van
dammeet
al
report
result
clinic
studi
influenza
vaccin
hollow
microneedl
devic
micronjet
use
local
advers
reaction
significantli
frequent
intramuscular
vaccin
mild
transient
natur
tci
immunogen
respons
increas
human
addit
safeti
efficaci
sever
microneedl
devic
assess
applic
vaccin
futur
clinic
studi
conduct
needlefre
easytous
lowinvas
lowcost
vaccin
method
perform
clinic
studi
origin
hydrogel
patch
formul
contain
combin
tt
dt
human
fig
b
safeti
assess
evalu
local
advers
respons
h
h
patch
remov
tci
formul
contain
tt
dt
shown
induc
local
sever
advers
event
fig
shown
fig
antitt
igg
antidt
igg
increas
pairedt
test
p
follow
first
vaccin
use
tci
formul
indic
singl
applic
tci
formul
could
induc
immun
respons
human
also
administ
second
vaccin
five
subject
neither
antibodi
titer
significantli
increas
first
vaccin
igg
titer
increas
part
subject
follow
second
vaccin
suggest
addit
applic
increas
efficaci
tci
formul
antibodi
titer
day
applic
tci
formul
maintain
higher
level
day
subject
examin
although
antibodi
titer
tend
lower
day
day
convent
patchbas
tci
system
requir
pretreat
disrupt
remov
sc
hydrogel
patch
achiev
ag
penetr
skin
without
remov
sc
agspecif
antibodi
produc
subject
singl
applic
human
repres
safeti
efficaci
advantag
also
conduct
clinic
evalu
tci
use
mh
fig
agfre
konideshap
coneshap
coneshap
tci
devic
appli
left
brachial
later
skin
fig
caus
seriou
local
system
advers
reaction
prepar
evalu
efficaci
vaccin
fig
use
trival
influenza
ha
ag
hacontain
coneshap
induc
haspecif
igg
respons
three
ha
ag
without
sever
advers
event
prepar
indic
mhbase
tci
system
safe
efficaci
human
simpl
easytous
lowinvas
effect
tci
formul
might
applic
mass
treatment
event
outbreak
increas
vaccin
rate
develop
countri
expect
tci
system
innov
vaccin
method
put
practic
use
earli
date
greatli
contribut
decreas
mortal
morbid
infecti
diseas
develop
vaccin
repres
basic
prophylaxi
infecti
diseas
draw
attent
worldwid
main
object
vaccin
develop
establish
manufactur
technolog
suppli
safe
effect
vaccin
ag
rapidli
stabli
problem
carri
enough
vaccin
prevent
infecti
diseas
remain
solv
order
distribut
vaccin
across
world
peopl
need
especi
develop
countri
easytous
lowcost
lowinvas
vaccin
method
instead
convent
inject
system
requir
tci
offer
attract
avenu
develop
needlefre
prophylaxi
main
challeng
address
develop
tci
system
ensur
accur
deliveri
ag
epidermi
dermi
sc
introduc
review
variou
approach
overcom
sc
barrier
develop
basic
preclin
clinic
studi
approach
conduct
recent
studi
demonstr
intraderm
vaccin
deliveri
skinresid
apc
increas
magnitud
immun
respons
rather
imi
exampl
studi
evalu
intraderm
deliveri
influenza
vaccin
suggest
dose
spare
rel
imi
achiev
nowaday
intanza
idflu
market
new
trival
inactiv
influenza
vaccin
administ
intraderm
rout
thu
tci
system
target
skin
immun
system
attract
vaccin
method
supplant
convent
imi
sci
term
eas
safeti
also
efficaci
practic
use
easytous
lowcost
lowinvas
effect
transcutan
vaccin
method
near
futur
would
contribut
global
countermeasur
infecti
diseas
would
greatli
benefit
countri
poor
vaccin
rate
exploratori
research
ministri
educ
cultur
sport
scienc
technolog
japan
grantinaid
mochida
memori
foundat
medic
pharmaceut
research
grantinaid
tokyo
biochem
research
foundat
conflict
interest
conflict
interest
